Infants and young children are at increased risk for respiratory syncytial virus (RSV) infections because of their maturing immune system and lack of prior exposure to RSV. A genetically stable live-attenuated RSV vaccine has been shown to be safe and immunogenic in RSV-seronegative children. Further research is ongoing in RSV-seropositive children. Current nasal vaccine is in the phase 2 stage with a very positive safety profile and is now being researched.
Patients must be:
Infants ages 6 mo to <22 months on the day of screening for the study
Born of full term greater to or equal to 37 weeks
Parents must bring birth certificate to show proof of birth parents
No known allergies to any other vaccines
No known household member that contains an immunocompromised illnesses
Duration of the study is 24 months with 6 visits to the clinic and 7 interim phone calls. Compensation up to $831.00.